Boston Scientific reported Q4 2024 revenue of $4.6B, beat analyst consensus of $4.4B by $140.5M. Diluted EPS came in at $0.70, beat the $0.66 consensus by $0.04. Boston Scientific reports across 2 business segments, led by Cardiovascular and MedSurg.
Trailing eight quarters through Q4 2024
Common questions about Boston Scientific's Q4 2024 earnings report.
Boston Scientific (BSX) reported Q4 2024 earnings on February 5, 2025 before market open.
Boston Scientific reported revenue of $4.6B and diluted EPS of $0.70 for Q4 2024.
Revenue beat the consensus estimate of $4.4B by $140.5M. EPS beat the consensus estimate of $0.66 by $0.04.
You can read the 10-K periodic report (0000885725-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.